

14:45 – 15:00

Good Machine Learning Practice (USA / UK)



Melissa Torres

Associate Director, U.S. Food and Drug Administration







ARTIFICIAL INTELLIGENCE (AI)/MACHINE LEARNING (ML) ENABLED MEDICAL DEVICES WORKING GROUP UPDATE

Co-Chairs: Matthew Diamond – US FDA Russell Pearson – UK MHRA

Background

Good Machine Learning Practice (GMLP) brings together high-level, fundamental principles important for the development, use and monitoring of Machine Learning (ML)-enabled medical devices.

ML-enabled products have unique considerations that can be addressed, at least in part, with GMLP implemented across the product life cycle.

Rapid technological advancements in Al/ML, combined with manufacturers from sectors beyond medical devices, makes development of GMLP an important priority to lower product and development risks and to protect against regulatory divergence.





Rationale

- There is a close interplay between ML-enabled medical devices and other software based medical devices.
 - GMLP must be developed to be compatible with best practice SaMD guidance and built upon existing core aspects of medical device regulations.
 - Core aspects include quality management systems, risk management and clinical evaluation to ensure the GMLP complements the state of the art and regulatory compliance.
- Work is aligned with the IMDRF Strategic Plan to develop a harmonized approach to the management of AI medical devices.
- Generating consensus across the product lifecycle via creation of a GMLP document will also assist with the IMDRF objectives to strengthen post-market activities and a total product lifecycle regulatory approach to medical devices.



Goal

- To develop a new document on the topic of Good Machine Learning Practice (GMLP) that will provide internationally harmonized principles to help promote the development of safe and effective ML-enabled medical devices.
 - Generate consensus on the key considerations for how AI/ML products can meet regulatory, risk management, quality management and clinical evaluation in order to promote consistency across jurisdictions.
 - Build upon the US FDA/Health Canada/UK MHRA joint document on GMLP Guiding Principles.



Good Machine Learning Practice Principles

FDA U.S. FOOD & DRUG



Medicines & Healthcare products Regulatory Agency

These guiding principles may be used to:

- Adopt good practices that have been proven in other sectors;
- Tailor practices from other sectors so they are applicable to medical technology and the health care sector; and
- Create new practices specific for medical technology and the health care sector.

| Good Machine Learning Practice for Medical Device Development: Guiding Principles | |
|--|---|
| Multi-Disciplinary Expertise are Leveraged | Good Software Engineering and Security Practices are |
| Throughout the Total Product Life Cycle | Implemented |
| Clinical Study Participants and Data Sets are Representative of the Intended Population | Training Data Sets are Independent of Test Sets |
| Selected Reference Datasets are Based Upon Best | Model Design is Tailored to the Available Data and |
| Available Methods | Reflects the Intended Use of the Device |
| Focus is Placed on the Performance of the | Testing Demonstrates Device Performance during |
| Human-Al Team | Clinically Relevant Conditions |
| Users are Provided Clear, Essential Information | Deployed Models are Monitored for Performance and Re-training Risks are Managed |



Current Status

- New Work Item Proposal approved in January 2022
- Working group is currently being established
 - Call for participants/representatives from IMDRF regulatory authorities, RHIs, and industry
 - IMDRF website updates
 - Expect work to begin in the next couple of weeks





Thank you! Questions?

Email <u>matthew.diamond@fda.hhs.gov</u> <u>Russell.Pearson2@mhra.gov.uk</u>

Disclaimer

This document was produced by the International Medical Device Regulators Forum. There are no restrictions on the reproduction or use of this document; however, incorporation of this document, in part or in whole, into another document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.

Copy right 2021 by the International Medical Device Regulators Forum.